2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

By sjmartinez • October 30, 2024

Bhimraj A, Falck-Ytter Y, Kim AY, Li JZ, Baden LR, Johnson S, Shafer RW, Shoham S, Tebas P, Bedimo R, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Martin GS, MacBrayne C, Nadig N, Nakamura MM, Shumaker AH, Tien P, Loveless J, Morgan RL, Gandhi RT. 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clin Infect Dis. 2024 Oct 29:ciae435. doi: 10.1093/cid/ciae435. Epub ahead of print. PMID: 39471458.

Tags: covid-19, guideline, Infectious Diseases, pemivibart, Pre-exposure prophylaxis, Publications, SARS-CoV-2

Enabled self-care for HIV infection: an inflection point for sustainable epidemic control

Joseph Davey D. Enabled self-care for HIV infection: an inflection point for sustainable epidemic control. Lancet Glob Health. 2027 Apr 14:103970. doi: 10.1016/j.langlo.2026.103970. Epub ahead[...]

Impact on daptomycin resistance using combination of daptomycin plus ceftaroline in daptomycin-susceptible and -resistant Staphylococcus aureus

Mishra NN, Black CA, Abdelhady W, Farah S, Rodas NA, Brizuela J, Lopez CB, Artaza JN, Sakoulas G, Rose WE. Impact on daptomycin resistance using[...]

DASC-LOT Framework and S3 Metric: A Novel Evaluation and Benchmarking Method to Assess Initiation, Duration, and Spectrum of Antimicrobial Usage at Inpatient Hospital Settings

Goto M, Imai S, Cho H, Merchant JA, Goetz MB, Perencevich EN, Alexander B, Shi Q, Holcombe A, Livorsi DJ. DASC-LOT Framework and S3 Metric:[...]